(Q27650932)

1

0 references

N Oumata

2

0 references

Y Ferandin

4

0 references

J A Endicott

5

0 references

H Galons

6

0 references

L Meijer

Roscovitine targets, protein kinases and pyridoxal kinase

7

0 references

language of work or name

English

0 references

publication date

2 October 2008

0 references

published in

Oncogene

0 references

volume

27

0 references

issue

44

0 references

page(s)

5797-807

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

The specificities of protein kinase inhibitors: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

The selectivity of protein kinase inhibitors: a further update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Coot: model-building tools for molecular graphics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Pharmacological inhibitors of cyclin-dependent kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Human members of the eukaryotic protein kinase family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2−Inhibitor Complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Mammalian cyclin-dependent kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

CDK inhibitors in cancer therapy: what is next?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

The protein kinase complement of the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Refinement of macromolecular structures by the maximum-likelihood method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Protein kinase resource: an integrated environment for phosphorylation research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Discovery and evaluation of dual CDK1 and CDK2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Purification of CK1 by affinity chromatography on immobilised axin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

7-Bromoindirubin-3'-oxime induces caspase-independent cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Cyclin-dependent kinase pathways as targets for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.191

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ONC.2008.191

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

4007313

1015205125

0 references

4007313

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference